The patent application (1) with priority date of 09. March 2020 claims that methyl bCD preferably with DS 0.7 (Crysmeb) itself or in combination with molnupiravir is effective for prevention or treatment of diseases caused by coronaviruses, such as SARS-CoV, SARS-CoV-2, MERS-CoV and mutants or variants thereof (1).
The compositions can be administered orally, parenterally, mucosally or cutaneously. The parenteral route preferably comprises subcutaneous, intravenous, intramuscular or in†raperi†oneal administration, although the latter is rather reserved for animals. The mucosal route preferably comprises nasal administration, pulmonary administration or administration via the rectal mucosa. The cutaneous route advantageously comprises the dermal route, in particular via a transdermal device, typically a patch.
The compositions can be formulated in the form of injectable suspensions, gels, oils, tablets, suppositories, powders, gel capsules, capsules, aerosols, etc., optionally by means of galenical forms or of devices which provide sustained and/or delayed release.
It was known earlier that coronaviruses can be inactivated via delipidation with methyl BCD for vaccine production (2) and (3).
(1) WO2021180742 – METHYL-CYCLODEXTRIN FOR USE IN TREATING ENVELOPED VIRUS INFECTIONS SUCH AS COV-2. (MELETIOS THERAPEUTICS)
(2) WO/2017/132059 INACTIVATION OF VIRUSES BY DELIPIDATION (Elanco US)
(3) 20180360945 INACTIVATION OF VIRUSES BY DELIPIDATION (Eli Lilly)